Skip to content
LATEST
Health

GSK wins FDA approval for Nelkarmi after 49% response rate

The accelerated clearance adds a post-treatment option for ALK-positive lung cancer and expands GSK’s oncology portfolio after its Nuvalent acquisition.

GSK wins FDA approval for Nelkarmi after 49% response rate

GSK said in a Nov. 18 SEC filing that the FDA approved Nelkarmi after a phase I/II trial showed a 49% response rate in one pretreated patient group.

The decision covers adults with locally advanced or metastatic ALK-positive non-small cell lung cancer after specified prior therapy, giving some patients a new option when earlier targeted treatments no longer control the disease.

Nelkarmi, also known as neladalkib, is an ALK-selective tyrosine kinase inhibitor, a targeted drug designed to block cancer-driving ALK signals. GSK said the FDA acted before its original Nov. 27 target action date and after Orphan Drug designation.

“Nelkarmi is our second new medicine approved in lung cancer this year,” Tony Wood, GSK’s chief scientific officer, said in the filing. He said the medicine was designed for ALK-positive non-small cell lung cancer through “broad coverage of ALK resistance mutations, ability to cross the blood-brain barrier and high target selectivity.”

The approval is for patients who previously received one ALK tyrosine kinase inhibitor, alectinib, or at least two prior ALK inhibitors and platinum-based chemotherapy in the unresectable locally advanced or metastatic setting, according to the filing.

In ALKOVE-1, a global single-arm phase I/II trial, GSK said the primary efficacy analysis supporting approval included 222 patients with previously treated ALK-positive non-small cell lung cancer. The wider trial enrolled 700 patients with ALK-positive solid tumors across phase I and phase II portions.

For patients previously treated with alectinib as their only prior ALK inhibitor, the confirmed overall response rate was 49%, or 33 of 67 patients, with a 95% confidence interval of 37% to 62%. Overall response rate measures the share of patients whose tumors shrink by a defined amount.

For patients who had received two or more prior ALK inhibitors and chemotherapy, the response rate was 32%, or 50 of 155 patients, with a 95% confidence interval of 24% to 40%. GSK said responses lasted at least six months in 76% and 69% of responders in the two groups, respectively.

Among patients with measurable central nervous system metastases at baseline, GSK reported intracranial response rates of 55% in the alectinib-only prior-treatment group and 26% in the group previously treated with two or more ALK inhibitors and chemotherapy.

Alice Shaw, an ALKOVE-1 investigator at Dana-Farber Cancer Institute, said: “The approval of neladalkib provides an important new treatment option for patients.”

The filing also described safety findings. GSK said the most common adverse reactions, occurring in at least 20% of patients, included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue. Permanent discontinuation because of adverse reactions occurred in 5% of patients, with hepatotoxicity the most frequent adverse reaction leading to discontinuation.

The study cannot show whether Nelkarmi improves overall survival or how it compares directly with other treatments, because ALKOVE-1 was a single-arm trial rather than a randomized study with a control group. The FDA’s accelerated approval pathway can allow earlier access based on measures such as response rate and duration of response.

GSK said Nelkarmi came from its recent acquisition of Nuvalent and is also being evaluated in ALKAZAR, an ongoing phase III trial in TKI-naïve ALK-positive non-small cell lung cancer, and in other solid tumors.

Source: SEC filing, GSK plc, Nov. 18, 2026

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news